Chalcogen Attached Directly To The Six-membered Hetero Ring By Nonionic Bonding Patents (Class 514/312)
-
Patent number: 10675366Abstract: The present disclosure provides a positron emission tomography (PET)-detectable 1-((2-fluoro-6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([18F]DASA-23) probe that can selectively bind to the pyruvate kinase variant M2 (PKM2) found in cancer cells, such as of human glioma. Given the importance of PKM2 in the regulation of tumor metabolism, there is an on-going need to non-invasively measure its expression through the development of PKM2-specific radiopharmaceuticals. Precursors useful for the synthesis of the radiolabeled [18F]DASA-23-PKM2-specific probe and related compounds, and their methods of synthesis, are provided. Since the half-life of the 18F isotope is approximately 110 min, it is advantageous for a practitioner to attach the radionuclide to the precursor shortly before administration. Therefore, a precursor compound suitable for receiving the radionuclide and capable of specifically binding to the PKM2 variant can be provided.Type: GrantFiled: August 11, 2017Date of Patent: June 9, 2020Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Corrine Gaye Beinat, Israt Shamima Alam, Michelle L. James, Sanjiv S. Gambhir, Ananth Srinivasan
-
Patent number: 10662207Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.Type: GrantFiled: April 7, 2017Date of Patent: May 26, 2020Assignee: Proteostasis Therapeutics, Inc.Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
-
Patent number: 10654807Abstract: Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.Type: GrantFiled: December 19, 2014Date of Patent: May 19, 2020Assignee: The University of KansasInventors: Sunil Abraham David, Hari Prasad Kokatla, Diptesh Sil, Subbalakshmi Malladi, Lauren Miranda Fox
-
Patent number: 10639299Abstract: Described herein are compounds that can bind CaSR and/or a CaSR extracellular domain and formulations thereof. Also described herein are methods of inhibiting CaSR and/or treating a disease or disorder associated with a mutation in CaSR by administering a compound or formulation thereof described herein. Also described herein are assays that can be used to identify compounds that can bind an extracellular domain of CaSR.Type: GrantFiled: March 29, 2017Date of Patent: May 5, 2020Assignees: Georgia State University Research Foundation, Inc., University of Georgia Research Foundation, Inc., Board of Trustees of Michigan State UniversityInventors: Jenny Jie Yang, Jian Hu, Edward Brown, Kelley Moremen
-
Patent number: 10588900Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.Type: GrantFiled: February 7, 2017Date of Patent: March 17, 2020Assignee: PHARMAKEA, INC.Inventors: Martin W. Rowbottom, John Howard Hutchinson
-
Patent number: 10583133Abstract: The present invention relates to a pharmaceutical composition comprising lenvatinib mesylate and a stabilizer in an amount of about 10% to about 20% based on the total weight of the composition, wherein the stabilizer is selected from the group consisting of calcium hydroxide and potassium hydroxide; and its process for preparation thereof.Type: GrantFiled: March 1, 2019Date of Patent: March 10, 2020Assignee: SHILPA MEDICARE LIMITEDInventors: Nijaguni Revansiddayya Rudraswamy Math, Sreenivas Reddy, Ravi Vamsi Peri, Krishnamurthy Toppaladoddi, Shivakumar Pradeep
-
Patent number: 10556883Abstract: Compounds having formula (I) are described. Also described, are methods of using these compounds to treat diseases, conditions, and disorders.Type: GrantFiled: February 1, 2017Date of Patent: February 11, 2020Assignee: GALDERMA RESEARCH & DEVELOPMENTInventors: Gilles Ouvry, Craig Steven Harris, Yushma Bhurruth-Alcor
-
Patent number: 10548888Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.Type: GrantFiled: July 3, 2018Date of Patent: February 4, 2020Assignee: EXELIXISInventors: Jo Ann Wilson, Khalid Shah
-
Patent number: 10508097Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.Type: GrantFiled: March 7, 2017Date of Patent: December 17, 2019Assignees: The Global Alliance for TB Drug Development, Inc., Janssen Pharmaceutica NVInventors: Anna Marie Upton, Christopher Blair Cooper, Koenraad Jozef Lodewijk Marcel Andries, Jerome Emile Georges Guillemont, Walter Marcel Mathilde Van den Broeck, Brian Desmond Palmer, Zhenkun Ma
-
Patent number: 10501418Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.Type: GrantFiled: February 16, 2015Date of Patent: December 10, 2019Assignee: Exelixis, Inc.Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
-
Patent number: 10501438Abstract: This application relates to aryl-substituted dihydroquinolinones of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to aryl-substituted dihydroquinolinones and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.Type: GrantFiled: August 11, 2016Date of Patent: December 10, 2019Assignee: Neomed InstituteInventors: Guillaume Jacquemot, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
-
Patent number: 10472342Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.Type: GrantFiled: April 12, 2019Date of Patent: November 12, 2019Assignee: FORMA THERAPEUTICS, INC.Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
-
Patent number: 10450286Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.Type: GrantFiled: April 19, 2019Date of Patent: October 22, 2019Assignee: FORMA THERAPEUTICS, INC.Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
-
Patent number: 10449189Abstract: Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient.Type: GrantFiled: June 24, 2016Date of Patent: October 22, 2019Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Akio Fujioka
-
Patent number: 10442817Abstract: The present invention includes novel RAD52 inhibitors for preventing or treating cancers in a subject in need thereof. The present invention further includes a method of preventing or treating cancers in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In certain embodiments, the subject is further administered at least one additional therapeutic agent.Type: GrantFiled: June 3, 2016Date of Patent: October 15, 2019Assignee: Drexel UniversityInventor: Alexander V. Mazin
-
Patent number: 10435389Abstract: The present invention relates to compounds capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds, and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.Type: GrantFiled: September 11, 2018Date of Patent: October 8, 2019Assignee: Krouzon Pharmaccuticals, Inc.Inventors: Robert Volkmann, Anthony Marfat, Frederick Nelson, Panayiotis Zagouras
-
Patent number: 10426767Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.Type: GrantFiled: April 5, 2018Date of Patent: October 1, 2019Assignee: Kura Oncolofy, Inc.Inventors: Antonio Gualberto, Catherine Rose Scholz
-
Patent number: 10426780Abstract: The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.Type: GrantFiled: December 1, 2016Date of Patent: October 1, 2019Assignee: ViiV Healthcare CompanyInventor: Mark Richard Underwood
-
Patent number: 10406149Abstract: A novel technique with which it is possible to suppress chemical degradation of a compound represented by general formula (1) or a salt thereof in an aqueous liquid formulation containing a compound represented by general formula (1) or a salt thereof. A method for suppressing the generation of a compound represented by general formula (2) or a salt thereof including containing a compound represented by general formula (1) or a salt thereof and a magnesium compound in an aqueous liquid formulation.Type: GrantFiled: June 2, 2016Date of Patent: September 10, 2019Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Wataru Minagawa, Hitoshi Kozuka, Mizuho Shibata, Takahiro Goto, Chifuyu Toriumi, Norihiro Kanayama
-
Patent number: 10407435Abstract: The present invention is a compound having the following formula: (Formula (I)) or a pharmaceutically acceptable salt thereof, wherein e.g. X is C or N; n is 1 to 10; each L is independently a 5- to 12-membered heteroaryl containing at least two nitrogen atoms; and W is a zinc-binding group. The compounds are useful as histone deacetylase (HDAC) inhibitors.Type: GrantFiled: October 29, 2015Date of Patent: September 10, 2019Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Somhairle MacCormick, William John Nodes, Cyrille Davy Tomassi
-
Patent number: 10399951Abstract: The present invention relates to compounds and compositions for inhibition of FASN, their synthesis, applications, and antidotes.Type: GrantFiled: August 31, 2018Date of Patent: September 3, 2019Assignee: FORMA THERAPEUTICS, INC.Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
-
Patent number: 10376504Abstract: The present invention is directed to azacyanoquinolinone compounds of the general structural formula: (wherein R5 and R6 are defined herein) which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: July 27, 2016Date of Patent: August 13, 2019Assignee: Merck, Sharp & Dohme Corp.Inventors: Antonella Converso, Kevin Rodzinak
-
Patent number: 10351568Abstract: Proteinopathies result from the proteasome not acting efficiently enough to eliminate harmful proteins and prevent the formation of the pathogenic aggregates. As described herein, inhibition of proteasome-associated deubiquitinase Usp14 results in increased proteasome efficiency. The present invention therefore provides novel compositions and methods for inhibition of Usp14, enhancement of proteasome activity and treatment of proteinopathies.Type: GrantFiled: November 5, 2015Date of Patent: July 16, 2019Assignee: President and Fellows of Harvard CollegeInventors: Daniel J. Finley, Randall W. King, Byung-Hoon Lee, Min Jae Lee, Timothy C. Gahman
-
Patent number: 10351527Abstract: This invention provides compound having a structure of Formulas: Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provide.Type: GrantFiled: April 9, 2015Date of Patent: July 16, 2019Assignees: THE UNIVERSITY OF BRITISH COLUMBIA, SIMON FRASER UNIVERSITYInventors: Paul Rennie, Artem Tcherkassov, Robert N. Young, Christophe M. Andre
-
Patent number: 10323036Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.Type: GrantFiled: October 13, 2017Date of Patent: June 18, 2019Assignee: Nimbus Lakshmi, Inc.Inventors: Jeremy Robert Greenwood, Geraldine C. Harriman, Silvana Marcel Leit de Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
-
Patent number: 10323029Abstract: The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.Type: GrantFiled: September 28, 2015Date of Patent: June 18, 2019Assignee: The Scripps Research InstituteInventors: Edward Roberts, Hugh Rosen, Mariangela Urbano, Miguel A. Guerrero
-
Patent number: 10300052Abstract: The present disclosure provides compounds effective in increasing mucociliary clearance in a subject. In one embodiment, the compounds are of the general formula I. The present disclosure further shows that such compounds are effective in increasing activation of the CFTR, thereby increasing mucociliary clearance in the subject. The present disclosure further shows that such compounds are effective in increasing the depth of ASL, thereby increasing mucociliary clearance in the subject. In one embodiment of each of the foregoing, the subject is free from congenital or genetic defect in the cellular mucociliary clearance apparatus and/or acquired abnormality in the cellular mucociliary clearance apparatus.Type: GrantFiled: April 28, 2017Date of Patent: May 28, 2019Assignee: The UAB Research FoundationInventors: Steven M Rowe, Mark Dransfield
-
Patent number: 10287265Abstract: Our invention relates to novel enantiomer derivatives of 8-hydroxyquinoline derivatives with general formula (I) and (II) and the synthesis thereof and pharmaceutically acceptable salts and metal complexes thereof, and the medicinal and/or pharmaceutical compositions comprising these compounds. The essence of the subject matter of the invention relates to the fact that prior art discloses the biological effect and characteristics only of the racemic products, the novel enantiomer derivatives according to the invention appear in our application for the first. The subject matter of the invention furthermore relates to a novel, stereoselective synthesis for the preparation of the novel enantiomer derivatives according to the invention. The novel medicinal and/or pharmaceutical compositions comprising these enantiomers are suitable for the treatment of the named diseases, and the enanatiomers are used for manufacture of these compositions.Type: GrantFiled: March 9, 2016Date of Patent: May 14, 2019Assignees: AVIDIN Co. Ltd., SONEAS Research Co. Ltd., Synaging SASInventors: László Puskás, István Kanizsai, Thierry Pillot, Márió Gyuris, András Szabó, Ferenc Takács, László Hackler
-
Patent number: 10267796Abstract: Embodiments of screening methods for determining test agents effective for modifying the appearance of pigmented skin are provided. The screening method may comprise the steps of contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADR?1 receptors, and determining based on the binding interaction of the test agent with the ADR?1 receptors whether the test agent is an effective ADR?1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein a test agent is considered to be an effective ADR?1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.Type: GrantFiled: October 21, 2011Date of Patent: April 23, 2019Assignee: The Procter & Gamble CompanyInventors: Leo Timothy Laughlin, II, Tomohiro Hakozaki, Wenzhu Zhao, Jiazhen Wang, John Crist Bierman
-
Patent number: 10251876Abstract: The present invention provides 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopro-pylamine used for combating a tumor. Specially, the present invention refers to method for treating tumor, pharmaceutical composition and medicinal kit related to the described compound. Administrating the compound with a suitable dosage regimen can not only make the patient's plasma concentration maintain the level of 100 ng/ml or lower, but also achieve effects of treatments and obtain benefits for various tumours.Type: GrantFiled: June 5, 2015Date of Patent: April 9, 2019Inventors: Shanchun Wang, Xunqiang Wang, Hongmei Gu, Ping Dong, Hongjiang Xu
-
Patent number: 10246443Abstract: Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R1, R2, R3 and R4 are each as defined in the present application.Type: GrantFiled: April 13, 2017Date of Patent: April 2, 2019Assignee: TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD.Inventors: Hesheng Zhang, Yingwei Chen, Qingchao He
-
Patent number: 10202367Abstract: Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.Type: GrantFiled: June 12, 2015Date of Patent: February 12, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of KansasInventors: Tsanyang Liang, Zongyi Hu, Juan Jose Marugan, Noel Terrence Southall, Shanshan He, Xin Hu, Jingbo Xiao, Marc Ferrer, Wei Zheng, Kevin J. Frankowski, Frank J. Schoenen, Kelin Li
-
Patent number: 10166225Abstract: This invention is directed to the treatment of osteoporosis using N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.Type: GrantFiled: September 20, 2012Date of Patent: January 1, 2019Assignee: Exelixis, Inc.Inventors: Dana T. Aftab, Douglas Clary
-
Patent number: 10166223Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes or fatty liver comprising a CYP4A (cytochrome P450A) inhibitor as an active ingredient. The compound of the present invention has activities of promoting glucose uptake into hepatocytes, inhibiting fat accumulation in liver cells, and inhibiting reactive oxygen production in mitochondria, and thus can be very usefully used for the development of a therapeutic agent for diabetes or fatty liver.Type: GrantFiled: May 18, 2018Date of Patent: January 1, 2019Assignee: KOREA BASIC SCIENCE INSTITUTEInventors: Gun Hwa Kim, Joo Hyun Park, Min Ji Lee
-
Patent number: 10159666Abstract: The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.Type: GrantFiled: March 17, 2015Date of Patent: December 25, 2018Assignee: Exelixis, Inc.Inventors: Dana T. Aftab, Sriram Naganathan, Wei Xu, Steven Lacy
-
Patent number: 10160726Abstract: This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.Type: GrantFiled: August 3, 2015Date of Patent: December 25, 2018Assignee: Novartis AGInventors: Javier de Vicente Fidalgo, Haiying He, Cheng Hu, Zhigan Jiang, Xiaolin Li, Peichao Lu, Wosenu Mergo, Daniel Mutnick, Folkert Reck, Alexey Rivkin, Colin Keith Skepper, Xiaojing Michael Wang, Jianhua Xia, Yongjin Xu
-
Patent number: 10150764Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: GrantFiled: July 18, 2014Date of Patent: December 11, 2018Assignee: Epizyme, Inc.Inventor: John Emmerson Campbell
-
Patent number: 10150763Abstract: A compound of the formula:(I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.Type: GrantFiled: May 8, 2017Date of Patent: December 11, 2018Assignee: Karus Therapeutics LimitedInventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
-
Patent number: 10125112Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.Type: GrantFiled: August 25, 2016Date of Patent: November 13, 2018Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik
-
Patent number: 10106502Abstract: A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.Type: GrantFiled: September 28, 2017Date of Patent: October 23, 2018Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, THE BROAD INSTITUTE, INC.Inventors: Longqin Hu, Sadagopan Magesh, Lin Chen, Timothy Lewis, Ben Munoz, Lili Wang
-
Patent number: 10093642Abstract: The present invention concerns compounds that selectively inhibit the activity of the Hedgehog (Hh) pathway, their preparation and uses thereof. The compounds of the present invention are useful in treating Hh-dependent tumors, such as medulloblastoma (MB).Type: GrantFiled: June 25, 2014Date of Patent: October 9, 2018Assignees: UNIVERSITÀ DEGLI STUDI DI ROMA “LA SAPIENZA”, UNIVERSITA DEGLI STUDI DI SIENAInventors: Bruno Botta, Alberto Gulino, Maurizio Botta, Mattia Mori, Lucia Di Marcotullio, Paola Infante, Francesca Ghirga, Sara Toscano, Cinzia Ingallina, Romina Alfonsi
-
Patent number: 10093628Abstract: The present invention pertains to a new compound E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl) benzyl)oxy)-benzylidene) hexanoic acid (MTTB), and its derivatives. The compounds of the invention are useful as selective peroxisome proliferator-activated receptor gamma (PPAR?) antagonists and are indicated for the use in the treatment of immune related diseases such as systemic inflammation, sepsis and septic shock.Type: GrantFiled: July 14, 2015Date of Patent: October 9, 2018Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖDERUNG DER ANGEWANDTEN FORSCHUNG E.V.Inventors: Tilo Knape, Andreas Von Knethen, Michael John Parnham, Manfred Schubert-Zsilavecz, Mario Wurglics, Daniel Flesch
-
Patent number: 10087171Abstract: The present invention relates to crystalline forms of cadazolid.Type: GrantFiled: December 18, 2017Date of Patent: October 2, 2018Inventors: Christian Hubschwerlen, Philippe Panchaud, Timo Rager, Jean-Luc Specklin
-
Patent number: 10077243Abstract: Provided herein are compounds of formula (I): and pharmaceutical compositions thereof, useful for the treatment of disorders mediated by metabotropic glutamate receptor 5.Type: GrantFiled: June 9, 2014Date of Patent: September 18, 2018Assignee: SUNOVION PHARMACEUTICALS INC.Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
-
Patent number: 10039757Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.Type: GrantFiled: February 7, 2017Date of Patent: August 7, 2018Assignee: Exelixis, Inc.Inventors: Jo Ann Wilson, Khalid Shah
-
Patent number: 10034873Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.Type: GrantFiled: June 2, 2017Date of Patent: July 31, 2018Assignee: Exelixis, Inc.Inventors: Jo Ann Wilson, Khalid Shah
-
Patent number: 10035771Abstract: The present invention discloses a class of mercaptonicotinic acid compound and preparation method and use thereof; the general structural formula of the compound is as shown in Formula I. Experiment demonstrates that the mercaptonicotinic acid compound could inhibit activity of botulinum toxin endopeptidase and tetanus toxin endopeptidase in vitro, which has a significant protective effect on botulinum toxin poisoning in mice, and can be used for preparing medicine intended to prevent and/or treat botulism, as well as to prevent botulinum toxin exposure and tetanus.Type: GrantFiled: May 19, 2014Date of Patent: July 31, 2018Assignee: INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES, PR CHINAInventors: Hui Wang, Wannian Zhng, Zhenyuan Miao, Tao Li, Xiong Liu, Yuelin Wu, Sen Luo, Chunquan Sheng, Xiaoxue Lu, Jianzhong Yao
-
Patent number: 10016408Abstract: The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.Type: GrantFiled: December 6, 2016Date of Patent: July 10, 2018Assignee: EMORY UNIVERSITYInventors: Lawrence J. Wilson, John Wiseman, Dennis C. Liotta, Michael G. Natchus
-
Patent number: 10017488Abstract: The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.Type: GrantFiled: February 6, 2015Date of Patent: July 10, 2018Assignee: Boston Biomedical, Inc.Inventors: Toshihiko Sone, Wataru Hirose, Naoaki Shimada, Chiang J. Li, Wei Li, David Leggett
-
Patent number: 10016409Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: GrantFiled: July 14, 2017Date of Patent: July 10, 2018Assignee: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Masafumi Ihara, Takakuni Maki, Akihiko Taguchi